|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CN118726313A
(zh)
|
2016-10-07 |
2024-10-01 |
综合Dna技术公司 |
化脓链球菌cas9突变基因和由其编码的多肽
|
|
US11242542B2
(en)
*
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
US11377645B2
(en)
|
2016-12-16 |
2022-07-05 |
The Rockefeller University |
Compositions and methods using Cas9 with enhanced spacer acquisition function
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
EP3565907B1
(en)
|
2017-01-06 |
2022-05-04 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
IT201700016321A1
(it)
|
2017-02-14 |
2018-08-14 |
Univ Degli Studi Di Trento |
Mutanti di cas9 ad alta specificita' e loro applicazioni.
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
KR20210060541A
(ko)
*
|
2018-09-19 |
2021-05-26 |
더 유니버시티 오브 홍콩 |
개선된 고처리량 조합 유전적 변형 시스템 및 최적화된 Cas9 효소 변이체
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020160125A1
(en)
*
|
2019-01-29 |
2020-08-06 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising an endonuclease and methods for purifying an endonuclease
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
WO2020257325A1
(en)
|
2019-06-17 |
2020-12-24 |
Vertex Pharmaceuticals Inc. |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
US20230174972A1
(en)
*
|
2019-10-15 |
2023-06-08 |
Agency For Science, Technology And Research |
Assays For Measuring Nucleic Acid Modifying Enzyme Activity
|
|
WO2021122944A1
(en)
|
2019-12-18 |
2021-06-24 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
|
CA3163463A1
(en)
*
|
2020-03-11 |
2021-09-16 |
Fuqiang Chen |
High fidelity spcas9 nucleases for genome modification
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
|
AU2021400745A1
(en)
|
2020-12-17 |
2023-07-20 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
|
CN112680430B
(zh)
*
|
2020-12-28 |
2023-06-06 |
南方医科大学 |
一种CRISPR SpCas9突变体及其应用
|
|
CN113005141A
(zh)
*
|
2021-01-05 |
2021-06-22 |
温州医科大学 |
高活性突变体构成的基因编辑工具及制备方法和修复先天性视网膜劈裂症致病基因的方法
|
|
CN112626070A
(zh)
*
|
2021-01-13 |
2021-04-09 |
海南微氪生物科技股份有限公司 |
一种基于切离酶基因编辑技术的定向修复系统
|
|
WO2022152746A1
(en)
|
2021-01-13 |
2022-07-21 |
Alia Therapeutics Srl |
K526d cas9 variants and applications thereof
|
|
WO2022238958A1
(en)
|
2021-05-12 |
2022-11-17 |
Crispr Therapeutics Ag |
Multiplex gene editing
|
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
|
EP4413146A2
(en)
*
|
2021-10-05 |
2024-08-14 |
The Board of Trustees of the Leland Stanford Junior University |
Treatment of polycythemia vera via crispr/aav6 genome editing
|
|
CN120265763A
(zh)
*
|
2023-10-25 |
2025-07-04 |
上海津曼特生物科技有限公司 |
靶向ttr的基因编辑组合物
|
|
CN117887760A
(zh)
*
|
2024-01-22 |
2024-04-16 |
中国医学科学院北京协和医院 |
SQSTM1/p62基因新致病突变c.1143delC的敲入小鼠模型及其构建方法
|
|
CN118497204B
(zh)
*
|
2024-07-16 |
2024-12-03 |
西北农林科技大学深圳研究院 |
一种质粒CRISPR-pCas9n及基因编辑的方法与应用
|